<DOC>
	<DOCNO>NCT01670929</DOCNO>
	<brief_summary>In woman unexplained recurrent miscarriage , progesterone ( 400 mg pessary , twice daily ) , start soon possible luteal phase positive pregnancy test continue 28 week gestation , compare placebo , ) .</brief_summary>
	<brief_title>Pr-conceptional Progesterone Unexplained Recurrent Miscarriage</brief_title>
	<detailed_description>Progesterone improve secondary outcome gestation delivery , on-going pregnancy 12 week , survival 28 day neonatal life . . Progesterone , compare placebo , incur substantial adverse effect mother neonate . Explore differential subgroup effect progesterone prognostic subgroup . . Perform economic evaluation cost-effectiveness .</detailed_description>
	<mesh_term>Abortion , Habitual</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>1 . Women unexplained recurrent miscarriage ( 2 consecutive first trim miscarriage ) . 2 . Age 1839 year randomisation ( likelihood miscarriage due chromosomal aberration higher old woman ; miscarriage unlikely prevent progesterone therapy ) . 3 . Spontaneous conception ( confirmed urinary pregnancy test ) . 4 . Willing able give inform consent . 1 . Age less twenty forty year old . 2 . Antiphospholipid syndrome ( lupus anticoagulant and/or anticardiolipin antibody [ IgG IgM ] ) ; recognise thrombophilic condition ( test accord usual clinic practice ) 3 . Intrauterine abnormality ( assess ultrasound , hysterosonography , hysterosalpingogram , hysteroscopy ) . 4 . Fibroids distort uterine cavity . 5 . Abnormal parental karyotype . 6 . Other identifiable cause recurrent miscarriage ( test initiate clinically indicate ) e.g. , diabetes , thyroid disease systemic lupus erythematosus ( SLE ) .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>recurrent miscarriage</keyword>
	<keyword>progesterone</keyword>
</DOC>